Penurunan Kaar Soluble Tumor Necrosis Factor Receptor Type 1 (sTNFRI) dalam Serum Penderita Psoriasis Vulgaris Setelah Diterapi dengan Krim Klobetasol Propionat 0,05% (Decreased Level of Serum sTFRI After Treatment with Clobetasol Propionate Cream 0.05%)

Psoriasis vulgaris is a chronic inflammatory skin disease characterized by variable features. The exact cause of psoriasis is still unknown but numerous studies have identified tumor necrosis factor-α (TNFα) as a cytokine regulating inflammatory cascade. TNF-α and its receptors (sTNFRI & sTNFRII) plays important roles in the induction of psoriatic lesions. Topical corticosteroid remain one of the most widely used treatment modalities for psoriasis. The aim of this study was to examine the level of sTNFRI before and after two weeks treatment with 0.05% clobetasol propionate cream and to examine correlation between the level of sTNFRI in patients with the severity of skin lesions. The study was a clinical trial without control with pre-post design and consecutive admission method. The assessment of the severity of skin lesions (Psoriasis Area and Severity Index PASI), and the serum concentration of sTNFRI (ELISA) were performed at baseline and after two weeks treatment. Wilcoxon and Pearson test were used for statistical analysis, and the level of very significance was set at p < 0.001 and the level of significance was set at p < 0.05. The result of the study showed nine (56.25%) males and seven (43.75%) females. The mean age was 35.8 years; range 16-70 years. Pretreatment PASI scores were 15.7 ± 10.4, range 3.0-38.4. After treatment, PASI scores were 4.4 ± 4.4, range 0-13.7 (Zw=3.513, p